A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings. Patients...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news